Natural antibodies, autoantibodies and complement activation in tissue injury

References

• Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and acquired immunity. Immunol Today 2000; 21: 624–630
   PubMedGoogle Scholar
• Carroll MC, Holers VM. Innate autoimmunity. Adv Immunol 2005; 86: 137–157
   PubMed Web of Science ®Google Scholar
• Carroll MC, Prodeus AP. Linkages of innate and adaptive immunity. Curr Opin Immunol 1998; 10: 36–40
   PubMed Web of Science ®Google Scholar
• Wener MH. Immune complexes and autoantibodies to C1q. Lupus: Molecular and cellular pathogenesis, GM Kammer, GC Tsokos. Humana Press, Totowa, NJ 1999; 574–598
   Google Scholar
• Kim SJ, Gershov D, Ma M, Brot N, Elkon KB. I-PLA2 activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 2002; 196: 655–665
   PubMed Web of Science ®Google Scholar
• Baumgarth N, Herman OC, Jager GC, Brown LE, Herzenberg LA, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med 2000; 192: 271–280
   PubMed Web of Science ®Google Scholar
• Boes M. Role of natural and immune IgM antibodies in immune responses. Mol Immunol 2000; 37: 1141–1149
   PubMed Web of Science ®Google Scholar
• Horn MP, Lacroix-Desmazes S, Stahl D, Miescher S, Stadler BM, Kazatchkine MD, Kaveri SV. Natural autoantibodies—benefits of recognizing “self”. Mod Asp Immunobiol 2001; 1: 267–270
   Google Scholar
• Avrameas S. Natural autoantibodies: From ‘horror autotoxicus’ to ‘gnothi seauton’. Immunol Today 1991; 12: 154–159
   PubMedGoogle Scholar
• Avrameas S, Ternynck T. Natural autoantibodies: The other side of the immune system. Res Immunol 1995; 146: 235–248
   PubMedGoogle Scholar
• Gobet R, Cerny A, Ruedi E, Hengartner H, Zinkernagel RM. The role of antibodies in natural and acquired resistance of mice to vesicular stomatitis virus. Exp Cell Biol 1988; 56: 175–180
   Google Scholar
• Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: Clues to a novel role for the classical complement pahtway in the maintenance of immune tolerance. Immunopharmacology 1999; 42: 47–52
   Google Scholar
• Holers VM. Complement as a regulatory and effector pathway in human diseases. Therapeutic interventions in the complement system, JD Lambris, VM Holers. Humana Press, Totowa 2000; 1–32
   Google Scholar
• Bos NA, Kimura H, Meeuwsen CG, De Visser H, Hazenberg MP, Wostmann BS, Pleasants JR, Benner R, Marcus DM. Serum immunoglobulin levels and naturally occurring antibodies against carbohydrate antigens in germ-free BALB/c mice fed chemically defined ultrafiltered diet. Eur J Immunol 1989; 19: 2335–2339
   Google Scholar
• Cukrowska B, Sinkora J, Rehakova Z, Sinkora M, Splichal I, Tuckova I, Avrameas S, Saalmuller A, Borat-Ciorbaur R, Tlaskalova-Hogenova H. Isotype and antibody specificity of spontaneously formed immunoglobulins in pig fetuses and germ-free piglets: Production by CD5- B cells. Immunology 1996; 88: 611–617
   Google Scholar
• Reid RR, Prodeus AP, Khan W, Hsu T, Rosen FS, Carroll MC. Unraveling the role of natural antibody and complement in the clearance of lipopolysaccharide. J Immunol 1997; 159: 970–975
   PubMed Web of Science ®Google Scholar
• Stahl D, Lacroix-Desmazes S, Barreau C, Sibrowski W, Kazatchkine MD, Kaveri SV. Altered antibody repertoires of plasma IgM and IgG toward nonself antigens in patients with warm autoimmune hemolytic anemia. Hum Immunol 2001; 62: 348–361
   Google Scholar
• Ahearn JM, Fischer MB, Croix D, Goerg S, Ma M, Xia J, Zhou X, Howard RG, Rothstein TL, Carroll MC. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an impaired B cell response to T-dependent antigen. Immunity 1996; 4: 251–262
   PubMed Web of Science ®Google Scholar
• Fleming SD, Mastellos D, Karpel-Massler G, Shea-Donohue T, Lambris JD, Tsokos GC. C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injury. Clin Immunol 2003; 108: 263–273
   PubMed Web of Science ®Google Scholar
• Hill J, Lindsay TF, Ortiz F, Yeh CG, Hechtman HB, Moore FD. Soluble complement receptor type 1 ameliorates the local and remote organ injury after intestinal ischemia–reperfusion in the rat. J Immunol 1992; 149: 1723–1728
   PubMed Web of Science ®Google Scholar
• Mollnes TE, Fosse E. The complement system in trauma-related and ischemic tissue damage: A brief review. Shock 1994; 2: 301–310
   PubMed Web of Science ®Google Scholar
• Rehrig S, Fleming SD, Anderson J, Guthridge JM, Rakstang J, McQueen CE, Holers VM, Tsokos GC, Shea-Donohue T. Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol 2001; 167: 5921–5927
   PubMedGoogle Scholar
• Stahl GL, Xu Y, Hao L, Miller M, Buras JA, Fung M, Zhao H. Role for the alternate complement pathway in ischemia/reperfusion injury. Am J Pathol 2003; 162: 449–455
   PubMed Web of Science ®Google Scholar
• Simpson R, Alon R, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Neutrophil and nonneutrophil-mediated injury in intestinal ischemia–reperfusion. Ann Surg 1993; 218: 444–453
   PubMed Web of Science ®Google Scholar
• Weisman HF, Bartow T, Leppo MK, Marsh HC, Carson GR, Concino MF, Boyle MP, Roux KH, Weisfeldt ML, Fearon DT. Soluble human complement receptor type 1: In vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science 1990; 146–151
   Google Scholar
• Hernandez LA, Grisham MB, Twohig B, Arfors KE, Harlan JM, Granger DN. Role of neutrophils in ischemia–reperfusion-induced microvascular injury. Am J Physiol 1987; 253: H699–H703
   PubMed Web of Science ®Google Scholar
• Williams JP, Pechet TTV, Weiser MR, Reid R, Kobzik L, Moore FD, Carroll MC, Hechtman HB. Intestinal reperfusion injury is mediated by IgM and complement. J Appl Physiol 1999; 86: 938–942
   PubMed Web of Science ®Google Scholar
• Fleming SD, Anderson J, Wilson F, Shea-Donohue T, Tsokos GC. C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion. Clin. Immunol. 2003; 105: 55–64
   Google Scholar
• Anderson J, Fleming S, Rehrig S, Tsokos G, Basta M, Shea-Donohue T. Intravenous immunoglobulin (IVIG) attenuates mesenteric ischemia–reperfusion injury. Clin Immunology 2005; 114: 137–146
   Google Scholar
• Karpel-Massler G, Fleming SD, Kirschfink M, Tsokos GC. Human C1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. J Surg Res 2003; 115: 247–256
   PubMed Web of Science ®Google Scholar
• Atkinson C, Song H, Lu B, Qiao F, Burns TA, Holers VM, Tsokos GC, Tomlinson S. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005; 115: 2444–2453
   PubMed Web of Science ®Google Scholar
• Fleming SD, Shea-Donohue T, Guthridge JM, Kulik L, Waldschmidt TJ, Gipson MG, Tsokos GC, Holers VM. Mice deficient in complement receptors 1 and 2 lack a tissue injury-inducing subset of the natural antibody repertoire. J Immunol 2002; 169: 2126–2133
   PubMed Web of Science ®Google Scholar
• Eror AT, Stojadinovic A, Starnes BW, Makrides SC, Tsokos GC, Shea-Donohue T. Anti-inflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin Immunol 1999; 90: 266–275
   PubMed Web of Science ®Google Scholar
• Reid RR, Woodcock S, Shimabukuro-Vornhagen A, Austen WG, Kobzik L, Zhang M, Hechtman HB, Moore FD, Carroll MC. Functional activity of natural antibody is altered in Cr2-deficient mice. J Immunol 2002; 169: 5433–5500
   PubMed Web of Science ®Google Scholar
• Hart ML, Ceonzo KA, Shaffer LA, Takahashi K, Rother RP, Reenstra WR, Buras JA, Stahl GL. Gastrointestinal ischemia–reperfusion injury is lectin complement pathway dependent without involving C1q. J Immunol 2005; 174: 6373–6380
   PubMed Web of Science ®Google Scholar
• Suankratay C., Zhang Y., Jones D., Lint T.F., Gewurz H. Enhancement of lectin pathway haemolysis by immunoglobulins. Clin Exp Immunol 1999; 117: 435–441
   Google Scholar
• Arnold JN, Wormald MR, Suter DM, Radcliffe CM, Harvey DJ, Dwek RA, Rudd PM, Sim RB. Human serum IgM glycosylation. J Biol Chem 2005; 280: 29080–29087
   PubMed Web of Science ®Google Scholar
• Malhotra R, Wormald MR, Rudd PM, Fischer PB, Dwek RA, Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med 1995; 1: 237–243
   PubMed Web of Science ®Google Scholar
• Lutz HU, Jelezarova E. Complement amplification revisited. Mol Immunol 2006; 43: 2–12
   PubMed Web of Science ®Google Scholar
• Holers VM, Girardi G, Mo L, Guthridge JM, Molina H, Pierangeli SS, Espinola R, Xiaowei LE, Mao D, Vialpando CG, Salmon JE. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211–220
   PubMed Web of Science ®Google Scholar
• Salmon JE, Girardi G, Holers VM. Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis. Ann Rheum Dis 2002; 61(Supp II)ii46–ii50
   Google Scholar
• Girardi G, Bulla R, Salmon JE, Tedesco F. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43: 68–77
   PubMed Web of Science ®Google Scholar
• Fleming SD, Egan RP, Girardi G, Holers VM, Salmon J, Monestier M, Tsokos GC. Anti-phospholipid antibodies restore mesenteric ischemia/reperfusion induced injury in complement receptor CR2/CR1 deficient mice. J Immunol 2004; 173: 7055–7061
   PubMedGoogle Scholar
• Theofilopoulos AN. Murine models of lupus. In: Lahita RG, editors. Systemic Lupus Erythematosus. 2nd ed. New York: Churchill Livingstone. p. 121–185.
   Google Scholar
• Eisenberg RA, Craven SY, Fisher CL, Morris SC, Rapoport R, Pisetsky DS, Cohen PL. The genetics of autoantibody production in MRL/lpr lupus mice. Clin Exp Rheumatol 1989; 7(Suppl 3)S35–S40
   Google Scholar
• Warren RW, Caster SA, Roths JB, Murphy ED, Pisetsky DS. The influence of the lpr gene on B cell activation: Differential antibody expression in lpr congenic mouse strains. Clin Immunol Immunopathol 1984; 31: 65–77
   Google Scholar
• Fleming SD, Monestier M, Tsokos GC. Accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. J Immunol 2004; 173: 4230–4235
   PubMedGoogle Scholar
• Zhang M, Austen WG, Chiu I, Alicot EM, Humg R, Ma M, Verna N, Xu M, Hechtman HB, Moore FD, Carroll MC. Identification of a specific self-reactive IgM antibody that initiates intestinal ischemia/reperfusion injury. Proc Natl Acad Sci USA 2004; 101: 3886–3891
   PubMed Web of Science ®Google Scholar
• Zhang M, Alicot EM, Chiu I, Li J, Verna N, Vorup-Jensen T, Kessler B, Shimaoka M, Chan R, Friend D, Mahmood U, Weissleder R, Moore FD, Carroll MC. Identification of the target self-antigens in reperfusion injury. J Exp Med 2006; 203: 141–152
   PubMed Web of Science ®Google Scholar
• Chan RK, Austen WG, Jr, Ibrahim S, Ding GY, Verna N, Hechtman HB, Moore FD, Jr. Reperfusion injury to skeletal muscle affects primarily type II muscle fibers. J Surg Res 2004; 122: 54–60
   Google Scholar
• Chan RK, Ding G, Verna N, Ibrahim S, Oakes S, Austen WG, Jr, Hechtman HB, Moore FD, Jr. IgM binding to injured tissue precedes complement activation during skeletal muscle ischemia–reperfusion. J Surg Res 2004; 122: 29–35
   Google Scholar
• Weiser MR, Williams JP, Moore FD, Kobzik L, Ma M, Hechtman HB, Carroll MC. Reperfusion injury of ischemic skeletal muscle is mediated by natural antibody and complement. J Exp Med 1996; 183: 2343–2348
   PubMed Web of Science ®Google Scholar
• Chan RK, Verna N, Afnan J, Zhang M, Ibrahim S, Carroll MC, Moore FD, Jr. Attenuation of skeletal muscle reperfusion injury with intravenous 12 amino acid peptides that bind to pathogenic IgM. Surgery 2006; 139: 236–243
   PubMed Web of Science ®Google Scholar
• Chan RK, Ibrahim SI, Verna N, Carroll M, Moore FD, Jr, Hechtman HB. Ischaemia–reperfusion is an event triggered by immune complexes and complement. Br J Surg 2003; 90: 1470–1478
   PubMed Web of Science ®Google Scholar
• Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004; 114: 501–507
   Google Scholar
• Erkkila AT, Narvanen O, Lehto S, Uusitupa MI, Yla-Herttuala S. Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease. Atherosclerosis 2005; 183: 157–162
   Google Scholar
• Fernvik EC, Ketelhuth DF, Russo M, Gidlund M. The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients. J Clin Immunol 2004; 24: 170–176
   PubMed Web of Science ®Google Scholar
• Wu R, Shen G, Morris R, Patnaik M, Peter JB. Elevated autoantibodies against oxidized palmitoyl arachidonoyl phosphocholine in patients with hypertension and myocardial infarction. J Autoimmun 2005; 24: 353–360
   Google Scholar
• Saevarsdottir S, Oskarsson OO, Aspelund T, Eiriksdottir G, Vikingsdottir T, Gudnason V, Valdimarsson H. Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk. J Exp Med 2005; 201: 117–125
   PubMedGoogle Scholar
• Jordan JE, Montalto MC, Stahl GL. Inhibition of mannose-binding lectin reduces postischemic myocardial reperfusion injury. Circulation 2001; 104: 1413–1418
   PubMed Web of Science ®Google Scholar
• Walsh MC, Bourcier T, Takahashi K, Shi L, Busche MN, Rother RP, Solomon SD, Ezekowitz AB, Stahl GL. Mannose-binding lectin is a regulator of inflammation that accompanies myocardial ischemia and reperfusion injury. J Immmunol 2005; 175: 541–546
   PubMedGoogle Scholar
• Davis WD, Brey RL. Antiphospholipid antibodies and complement activation in patients with cerebral ischemia. Clin Exp Rheumatol 1992; 10: 455–460
   PubMedGoogle Scholar
• Pedersen ED, Waje-Andreassen U, Vedeler CA, Aamodt G, Mollnes TE. Systemic complement activation following human acute ischaemic stroke. Clin Exp Immunol 2004; 137: 117–122
   PubMed Web of Science ®Google Scholar
• van Beek J, Elward K, Gasque P. Activation of complement in the central nervous system: Roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 2003; 992: 56–71
   PubMed Web of Science ®Google Scholar
• Van Beek J, Chan P, Bernaudin M, Petit E, MacKenzie ET, Fontaine M. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia 2000; 31: 39–50
   PubMed Web of Science ®Google Scholar
• Janardhan V, Wolf PA, Kase CS, Massaro JM, D'Agostino RB, Franzblau C, Wilson PW. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke 2004; 35: 736–741
   Google Scholar
• di Somone N, Meroni PL, de Papa N, Raschi E, Caliandro D, De Carolis CS, Khamashta MA, Atsumi T, Hughes GR, Balestrieri G, Tincani A, Casali P, Caruso A. Antiphospholipid antibodies affect trophoblast gonadotropin secretion and invasiveness by binding directly and through adhered beta2-glycoprotein I. Arthritis Rheum 2000; 43: 140–150
   Google Scholar
• Ambrus G, Gal P, Kojima M, Szilagyi K, Balczer J, Antal J, Graf L, Laich A, Moffatt BE, Schwaeble W, Sim RB, Zavodszky P. Natural substrates and inhibitors of mannan-binding lectin-associated serine protease-1 and -2: A study on recombinant catalytic fragments. J Immunol 2003; 170: 1374–1382
   PubMedGoogle Scholar
• Gulati S, Sastry K, Jensenius JC, Rice PA, Ram S. Regulation of the mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1-inhibitor and alpha 2-macroglobulin. J Immunol 2002; 168: 4078–4086
   Google Scholar
• Matsushita M, Thiel S, Jensenius JC, Terai I, Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J Immunol 2000; 165: 2637–2642
   PubMed Web of Science ®Google Scholar
• Jiang H, Wagner E, Zhang H, Frank MM. Complement 1 inhibitor is a regulator of the alternative complement pathway. J Exp Med 2001; 194: 1609–1616
   PubMed Web of Science ®Google Scholar
• Sekine H, Reilly CM, Molano ID, Garnier G, Circolo A, Ruiz P, Holers VM, Boackle SA, Gilkeson GS. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001; 166: 6444–6451
   Google Scholar
• Sheerin NS, Springall T, Carroll MC, Hartley B, Sacks SH. Protection agains anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997; 110: 403–409
   PubMed Web of Science ®Google Scholar
• Arumugam TV, Shiels IA, Strachan AJ, Abbenante G, Fairlie DP, Taylor SM. A small molecule C5a receptor antagonist protects kidneys from ischemia/reperfusion injury in rats. Kidney Int 2003; 63: 134–142
   PubMed Web of Science ®Google Scholar
• Zhou W, Farrar CA, Abe K, Pratt JR, Marsh JE, Wang Y, Stahl GL, Sacks SH. Predominant role of C5b-9 in renal ischemia/reperfusion injury. J Clin Invest 2000; 105: 1363–1371
   PubMed Web of Science ®Google Scholar
• Park J, Haas M, Cunningham PN, Bao L, Alexander JJ, Quigg RJ. Injury in renal ischemia–reperfusion is independent from immunoglobulins and T lymphocytes. Am J Physiol 2002; 282: F352–F357
   Web of Science ®Google Scholar
• Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 2003; 170: 1517–1523
   PubMed Web of Science ®Google Scholar
• Tsokos GC, Fleming SD. Autoimmunity, complement activation, tissue injury and reciprocal effects. Curr Dir Autoimmun 2004; 7: 149–164
   Google Scholar